Reformatting palivizumab and motavizumab from IgG to human IgA impairs their efficacy against RSV infection in vitro and in vivo

Author(s):
Jacobino, S.R.; Nederend, M.; Reijneveld, J.F.; Augustijn, D.; Jansen, J.H.M.; Meeldijk, J.; Reiding, K.R.; Wuhrer, M. (0000-0002-0814-4995); Coenjaerts, F.E.J.; Hack, C.E.; Bont, L.J.; Leusen, J.H.W.
Published
2018
Publication type
Article / Letter to editor
antibody glycosylationdIgAFc receptorfusion proteinIgGmIgAmotavizumabneutralizing antibodiespalivizumabRSVsIgA
Date issued
2018-12-31
Language
English
Is part of
mAbs (2018), Vol. 10, no. 3, p. 453-462
hdl
1887/75389
doi
10.1080/19420862.2018.1433974
URL
https://www.tandfonline.com/doi/full/10.1080/19420862.2018.1433974